吸入的布德索尼德和肺部沙尔科毒性再审
Olof Selroos1, Ralph Brattsand1
1Independent researcher.
概括
吸入性皮质类固醇 (ICS),特别是布塞尼德 (BUD),在肺部类固醇症的维持治疗中表现出一些疗效. 进一步的研究可能会产生更好的系统风险概况的ICS,用于治疗肺部疾病.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 肺性沙尔科毒症是一种复杂的炎症性疾病,影响肺部.
- 吸入性皮质类固醇 (ICS) 已被研究用于治疗肺部类固醇症,结果有限但值得注意.
- 布索尼德 (BUD) 在特定的治疗环境中表现特别有前途.
研究的目的:
- 审查和总结ICS在肺癌沙尔科病的使用临床证据.
- 探索布索尼德功效背后的药理动力学和药理动力学机制.
- 为了确定潜在的未来方向,ICS-based治疗在肉类瘤.
主要方法:
- 对有控制的临床研究进行系统审查,这些临床研究涉及ICS在肺部类固醇症中.
- 对吸入布德索尼德的药理动力学数据的分析,包括系统吸收和局部转化.
- 与其他ICS和全身性皮质类固醇药物相比,布迪索尼德的疗效.
主要成果:
- 有控制的研究表明,ICS,主要是布松胺 (BUD),在肺癌沙丘症中有一定的疗效.
- 在最初的全身性皮质类固醇治疗或复发后,BUD的有效性主要观察到在维持治疗中.
- 关于BUD有效性的建议机制包括通过BUD-oleate形成快速的全身吸收和长时间的局部抗炎活性.
结论:
- 目前的ICS,包括BUD,一般不推用于常规的类固醇治疗.
- 布德索尼德的药理动力学概况为开发未来的ICS提供了洞察力,可以优化呼吸道与全身活性.
- 进一步的研究可能会导致新的ICS,减少对肺部疾病的口服皮质类固醇的依赖.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
186
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
186
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
227
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
227
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
238
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
238
01:23Inhaled Medications
240
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
240